Aldeyra Therapeutics, Inc. Annual Nonoperating Income (Expense) in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Aldeyra Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2013 to 2023.
  • Aldeyra Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $1.16M, a 14.4% decline year-over-year.
  • Aldeyra Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $5.18M, a 45.1% increase year-over-year.
  • Aldeyra Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $5.25M, a 701% increase from 2022.
  • Aldeyra Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $655K.
  • Aldeyra Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.56M, a 3.43% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $5.25M +$4.6M +701% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 $655K +$2.21M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 -$1.56M +$55.2K +3.43% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$1.61M -$2.55M -272% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 $938K +$132K +16.3% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
2018 $806K +$658K +445% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
2017 $148K +$151K Jan 1, 2017 Dec 31, 2017 10-K 2019-03-08
2016 -$3.47K +$97.7K +96.6% Jan 1, 2016 Dec 31, 2016 10-K 2017-03-30
2015 -$101K -$2.18M -105% Jan 1, 2015 Dec 31, 2015 10-K 2017-03-30
2014 $2.08M -$14.7M -87.6% Jan 1, 2014 Dec 31, 2014 10-K 2016-03-30
2013 $16.7M Jan 1, 2013 Dec 31, 2013 10-K 2015-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.